NCT02768766 is a Phase 1 clinical trial of Selumetinib, 100mg in Uveal Melanoma, sponsored by Shaheer A. Khan.

Who is sponsoring NCT02768766?

NCT02768766 is sponsored by Shaheer A. Khan.

What drugs are being tested in NCT02768766?

Interventions in NCT02768766: Selumetinib, 100mg, Selumetinib, 125mg, Selumetinib, 150mg, Selumetinib, 175mg, Selumetinib, 200mg, Selumetinib, 225mg.

What condition does NCT02768766 study?

NCT02768766 studies Uveal Melanoma.

Is NCT02768766 still recruiting?

NCT02768766 is currently completed. Last updated 31 August 2023.

Last reviewed 2023-08-31 · How we verify

NCT02768766

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intermittent Selumetinib for Uveal Melanoma

Completed Phase 1 Last updated 31 August 2023

What this trial tests

Phase 1 trial testing Selumetinib, 100mg in Uveal Melanoma in 42 participants. Completed in 18 September 2020.

Timeline

28 February 2017

Primary endpoint
18 September 2020

18 September 2020

Quick facts

Lead sponsor	Shaheer A. Khan
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	28 February 2017
Primary completion	18 September 2020
Estimated completion	18 September 2020
Sites	3 locations across United States

Drugs / interventions tested

Selumetinib, 100mg — full drug profile →
Selumetinib, 125mg — full drug profile →
Selumetinib, 150mg — full drug profile →
Selumetinib, 175mg — full drug profile →
Selumetinib, 200mg — full drug profile →
Selumetinib, 225mg

Conditions studied

Uveal Melanoma — all drugs for Uveal Melanoma →

Sponsor

Shaheer A. Khan — full company profile →

Who can join

18 and older, any sex, with Uveal Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the drug Selumetinib will have on subjects with uveal melanoma. Selumetinib is a drug that blocks (or turns off) methyl ethyl ketone (MEK), a protein activated in some uveal melanoma cells. Selumetinib is a MEK inhibitor. Blocking MEK may stop the cancer from growing.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Treatment of uveal melanoma: where are we now?
Yang J, Manson DK, Marr BP, Carvajal RD. · · 2018 · cited 229× · PMID 29497459 · DOI 10.1177/1758834018757175
The biology of uveal melanoma.
Amaro A, Gangemi R, Piaggio F, Angelini G, et al · · 2017 · cited 155× · PMID 28229253 · DOI 10.1007/s10555-017-9663-3
Targeting the ERK Signaling Pathway in Melanoma.
Savoia P, Fava P, Casoni F, Cremona O. · · 2019 · cited 137× · PMID 30934534 · DOI 10.3390/ijms20061483
Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine.
Lee YT, Tan YJ, Oon CE. · · 2023 · cited 80× · PMID 36873180 · DOI 10.1016/j.apsb.2022.09.010
<i>GNAQ</i> and <i>GNA11</i> Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma.
Silva-Rodríguez P, Fernández-Díaz D, Bande M, Pardo M, et al · · 2022 · cited 80× · PMID 35804836 · DOI 10.3390/cancers14133066
Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives.
Croce M, Ferrini S, Pfeffer U, Gangemi R. · · 2019 · cited 68× · PMID 31216772 · DOI 10.3390/cancers11060846
Uveal melanoma: progress in molecular biology and therapeutics.
Li Y, Shi J, Yang J, Ge S, et al · · 2020 · cited 41× · PMID 33149769 · DOI 10.1177/1758835920965852
Current Melanoma Treatments: Where Do We Stand?
Moreira A, Heinzerling L, Bhardwaj N, Friedlander P. · · 2021 · cited 36× · PMID 33435389 · DOI 10.3390/cancers13020221

Verify or expand the search:

Other recruiting trials for Uveal Melanoma

Currently open trials in the same condition.

NCT07421739 — Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects · recruiting
NCT06070012 — Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06932757 — Adjuvant Quisinostat in High-Risk Uveal Melanoma · Phase 2 · recruiting
NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
NCT06519266 — PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02768766 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shaheer A. Khan
Last refreshed: 31 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02768766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing